The ethical dilemma of gene editing: Our reporter took your questions
By Carolyn Y. Johnson,
The Washington Post [cites CGS’ Pete Shanks ]
| 12. 08. 2023
The first medicine based on gene editing, a one-time therapy for sickle cell disease, was just approved in the United States. It’s a big moment for patients with sickle cell disease and for the technology called CRISPR, which powers the therapy.
I am Carolyn Johnson, a science reporter at The Washington Post, and I’ve been following the speedy trajectory of CRISPR from a scientific breakthrough in 2012 to a medicine that can alleviate human suffering 11 years later. On Tuesday, I answered your questions about the potential of this technology to transform medicine — and the challenges associated with it.
First, a quick primer: CRISPR is often compared to a pair of “molecular scissors” that can make targeted cuts in DNA, giving scientists the ability to easily and precisely alter the genome. Scientists often hear from families afflicted by genetic diseases hoping that this technology will help save their loved ones. It has also spurred controversies — including battles over who invented CRISPR and the fear that it will be used to create “designer babies.”
Here...
Related Articles
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Katherine Drabiak, Journal of Medical Ethics Forum | 08.07.2025
Adapted from Mitochondrial DNA at
National Human Genome Research Institute
Recently, media outlets around the world have been reporting on children born from pronuclear genome transfer (sometimes called “3-parent IVF,” “mitochondrial donation” or “mitochondrial replacement therapy”) at Newcastle Fertility Center...
By Nicky Hudson, The Conversation | 08.12.2025